CN105796566A - Medicine for treating upper respiratory tract infection in children - Google Patents
Medicine for treating upper respiratory tract infection in children Download PDFInfo
- Publication number
- CN105796566A CN105796566A CN201610218414.0A CN201610218414A CN105796566A CN 105796566 A CN105796566 A CN 105796566A CN 201610218414 A CN201610218414 A CN 201610218414A CN 105796566 A CN105796566 A CN 105796566A
- Authority
- CN
- China
- Prior art keywords
- respiratory tract
- upper respiratory
- tract infection
- pharmaceutical composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to medicine composition for treating upper respiratory tract infection in children. The medicine composition is prepared from an effective dose of a compound and a pharmaceutically-acceptable carrier, wherein the compound has the structure shown in the specification. The medicine composition has a remarkable resisting effect on pathogenic bacteria causing the upper respiratory tract infection in children, and the medicine can be developed into new clinically effective medicine composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of medicine treating infant upper respiratory tract infection.
Background technology
Upper respiratory tract infection is one of modal disease of children's, is especially more common in winter-spring season.The Etiological causing upper respiratory tract infection is virus, and minority is to be caused by antibacterial or mycoplasma pneumoniae.Mild mainly stream clear water nasal mucus, sneeze, slightly cough, pharyngalgia, tired, indigestion and loss of appetite, can have low grade fever, about 3-4 days of the course of disease, minority continues more than 1 week；Children with serious disease can accompany high heat, hacking cough, agitation, minority can have hyperpyrexia convulsion.Prognosis is generally good, but weakling can cause the complication such as otitis media, cervical lymphadenitis, retropharyngeal abscess, and only a few case can lead to viral myocarditis.Spread downwards such as inflammation and can cause bronchitis or pneumonia.On the basis of viral infection, usually merge antibacterial infect.Infant upper respiratory tract infection is many to be caused by various pathogenic bacterium, finds that bacteroides thetaiotaomicron ATCC29741 is one of wherein important pathogenic bacterium in the recent period.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating infant upper respiratory tract infection.
In order to realize the purpose of the present invention, the present invention provides a kind of pharmaceutical composition treating infant upper respiratory tract infection, and described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
Wherein
R is H, CH3、OCH3Or Ph, it is preferable that R is Ph.
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
The present invention also provides for compound purposes in the medicine of preparation vitro inhibition bacteroides thetaiotaomicron ATCC29741, and this compound has having structure:
Wherein
R is Ph.
Term used herein " pharmaceutically acceptable " refers to the material of biologic activity or the character not eliminating compound as herein described, such as carrier or diluent.This kind of material is applied to individuality and is not resulted in undesirable biological action or not with harmful way and any component interaction in the compositions comprising it.
" pharmaceutically acceptable carrier " includes any and all of solvent as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, preservative (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, preservative, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition.
The pharmaceutical composition of the present invention is notable for the pathogen effect causing infant upper respiratory tract infection, it is possible to develop into pharmaceutical composition effectively new clinically.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art's basic thought according to the present invention, various modifications may be made or improves, but without departing from the basic thought of the present invention, all within the scope of the present invention.
The research of experimental example the compounds of this invention purposes in the medicine of preparation vitro inhibition bacteroides thetaiotaomicron ATCC29741
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
Wherein R is Ph.
For examination strain bacteroides thetaiotaomicron ATCC29741 purchased from Shanghai Kun Ken biochemical industry company limited.
Culture fluid
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities company limited of BeiJing ZhongKe.
Test method
Bacteroides thetaiotaomicron ATCC29741 is inoculated in agar plate nutritional solution plane, uniformly gathers during inoculation.
Weighing target compound 0.01 gram, add 20000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritional solution plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 18 hours.Measure the diameter of antibacterial ring.Measure and average for 3 times.
1.4 results
The average diameter of the antibacterial ring of bacteroides thetaiotaomicron ATCC29741 is 14.51mm, and this shows that target compound has the effect of extremely strong vitro inhibition bacteroides thetaiotaomicron ATCC29741.
Claims (7)
1. the pharmaceutical composition treating infant upper respiratory tract infection, it is characterised in that described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
Wherein
R is H, CH3、OCH3Or Ph.
2. the pharmaceutical composition for the treatment of infant upper respiratory tract infection according to claim 1, it is characterised in that R is Ph.
3. the pharmaceutical composition for the treatment of infant upper respiratory tract infection according to claim 2, it is characterised in that described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent.
4. the pharmaceutical composition for the treatment of infant upper respiratory tract infection according to claim 3, it is characterised in that described diluent is sugar derivatives, starch derivatives or cellulose derivative.
5. the pharmaceutical composition for the treatment of infant upper respiratory tract infection according to claim 4, it is characterised in that described diluent is lactose.
6. the pharmaceutical composition for the treatment of infant upper respiratory tract infection according to claim 3, it is characterised in that described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
7. compound purposes in the medicine of preparation vitro inhibition bacteroides thetaiotaomicron ATCC29741, it is characterised in that this compound has having structure:
Wherein
R is Ph.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610218414.0A CN105796566A (en) | 2016-04-08 | 2016-04-08 | Medicine for treating upper respiratory tract infection in children |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610218414.0A CN105796566A (en) | 2016-04-08 | 2016-04-08 | Medicine for treating upper respiratory tract infection in children |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105796566A true CN105796566A (en) | 2016-07-27 |
Family
ID=56459825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610218414.0A Pending CN105796566A (en) | 2016-04-08 | 2016-04-08 | Medicine for treating upper respiratory tract infection in children |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105796566A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006113615A2 (en) * | 2005-04-15 | 2006-10-26 | Sloan-Kettering Institute For Cancer Research | Anti-microbial agents and uses thereof |
-
2016
- 2016-04-08 CN CN201610218414.0A patent/CN105796566A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006113615A2 (en) * | 2005-04-15 | 2006-10-26 | Sloan-Kettering Institute For Cancer Research | Anti-microbial agents and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| 汪复主编: "《感染性疾病与抗微生物治疗》", 31 October 2008, 复旦大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105796566A (en) | Medicine for treating upper respiratory tract infection in children | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN102218047A (en) | Medicament for treating drug-resistant bacteria infection, and application of active ingredient thereof in pharmacy | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN107158052A (en) | Application of the Herba Melastomatis dodecandri extract in medicine is prepared | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105769899B (en) | A kind of medicine treating infantile pneumonia | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN108992478A (en) | The application of Aralia wood extract in medicine preparation | |
| CN108926583A (en) | The purposes of Zhejiang wintersweet anti-microbial infection | |
| CN108926585A (en) | Application of the wintersweet genus plants extract in pharmacy | |
| CN105232504B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly | |
| CN105748478A (en) | Medicine for treating infantile diarrhea | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| TWI703979B (en) | Use of mung bean peel alcohol extract for preparing antiviral pharmaceutical composition | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160727 |